探花精选

Katja Petzold

Katja Petzold

Principal Researcher | Docent
Telephone: +46852487647
Visiting address: Solnav盲gen 9, 9B, 17177 Stockholm
Postal address: C2 Medicinsk biokemi och biofysik, C2 Molekyl盲r strukturbiologi Petzold, 171 77 Stockholm

Articles

  • Journal article: NUCLEIC ACIDS RESEARCH. 2025;53(13):gkaf633
    Sweetapple L; Kosek DM; Banijamali E; Becker W; Mueller J; Karadiakos C; Baronti L; Guzzetti I; Schritt D; Chen A; Andersson ER; Petzold K
  • Article: NUCLEIC ACIDS RESEARCH. 2025;53(8):gkaf364
    Kosek DM; Petzold K; Andersson ER
  • Journal article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2025;64(10):e202421062
    Brauser M; Petzold K; Thiele CM
  • Journal article: JOURNAL OF BIOMOLECULAR NMR. 2024;78(4):249-264
    Annecke HTP; Eidelpes R; Feyrer H; Ilgen J; Guerdap CO; Dasgupta R; Petzold K
  • Journal article: NUCLEIC ACIDS RESEARCH. 2024;52(19):11995-12004
    Dasgupta R; Becker W; Petzold K
  • Article: BRITISH JOURNAL OF PHARMACOLOGY. 2024;181(20):3819-3835
    Gratz L; Sajkowska-Kozielewicz JJ; Wesslowski J; Kinsolving J; Bridge LJ; Petzold K; Davidson G; Schulte G; Kozielewicz P
  • Article: NUCLEIC ACIDS RESEARCH. 2023;51(20):11162-11177
    Kosek DM; Banijamali E; Becker W; Petzold K; Andersson ER
  • Article: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2023;145(19):10659-10668
    Sahin C; Motso A; Gu X; Feyrer H; Lama D; Arndt T; Rising A; Gese GV; Haellberg BM; Marklund EG; Schafer NP; Petzold K; Teilum K; Wolynes PG; Landreh M
  • Article: RNA. 2023;29(3):317-329
    Banijamali E; Baronti L; Becker W; Sajkowska-Kozielewicz JJ; Huang T; Palka C; Kosek D; Sweetapple L; Mueller J; Stone MD; Andersson ER; Petzold K
  • Article: NATURE COMMUNICATIONS. 2022;13(1):5750
    Clemente P; Calvo-Garrido J; Pearce SF; Schober FA; Shigematsu M; Siira SJ; Laine I; Spahr H; Steinmetzger C; Petzold K; Kirino Y; Wibom R; Rackham O; Filipovska A; Rorbach J; Freyer C; Wredenberg A
  • Article: PLOS ONE. 2022;17(7):e0264662
    Feyrer H; Gurdap CO; Marusic M; Schlagnitweit J; Petzold K
  • Article: NATURE PROTOCOLS. 2021;16(11):5146-5170
    Riad M; Hopkins N; Baronti L; Karlsson H; Schlagnitweit J; Petzold K
  • Journal article: JOVE-JOURNAL OF VISUALIZED EXPERIMENTS. 2021;(173)
    Feyrer H; Schlagnitweit J; Petzold K
  • Article: JOVE-JOURNAL OF VISUALIZED EXPERIMENTS. 2021;(173)
    Feyrer H; Schlagnitweit J; Petzold K
  • Article: CURRENT PROTOCOLS. 2021;1(6):e159
    Karlsson H; Feyrer H; Baronti L; Petzold K
  • Article: BIOMOLECULAR NMR ASSIGNMENTS. 2021;15(1):203-211
    Schnieders R; Peter SA; Banijamali E; Riad M; Altincekic N; Bains JK; Ceylan B; Fuertig B; Gruen JT; Hengesbach M; Hohmann KF; Hymon D; Knezic B; Oxenfarth A; Petzold K; Qureshi NS; Richter C; Schlagnitweit J; Schlundt A; Schwalbe H; Stirnal E; Sudakov A; Voegele J; Wacker A; Weigand JE; Wirmer-Bartoschek J; Woehnert J
  • Article: NUCLEIC ACIDS RESEARCH. 2020;48(22):12415-12435
    Wacker A; Weigand JE; Akabayov SR; Altincekic N; Bains JK; Banijamali E; Binas O; Castillo-Martinez J; Cetiner E; Ceylan B; Chiu L-Y; Davila-Calderon J; Dhamotharan K; Duchardt-Ferner E; Ferner J; Frydman L; Fuertig B; Gallego J; Gruen JT; Hacker C; Haddad C; Haehnke M; Hengesbach M; Hiller F; Hohmann KF; Hymon D; de Jesus V; Jonker H; Keller H; Knezic B; Landgraf T; Loehr F; Luo L; Mertinkus KR; Muhs C; Novakovic M; Oxenfarth A; Palomino-Schatzlein M; Petzold K; Peter SA; Pyper DJ; Qureshi NS; Riad M; Richter C; Saxena K; Schamber T; Scherf T; Schlagnitweit J; Schlundt A; Schnieders R; Schwalbe H; Simba-Lahuasi A; Sreeramulu S; Stirnal E; Sudakov A; Tants J-N; Tolbert BS; Voegele J; Weiss L; Wirmer-Bartoschek J; Martin MAW; Wohnert J; Zetzsche H
  • Article: RNA. 2020;26(8):1023-1037
    Karlsson H; Baronti L; Petzold K
  • Article: NATURE. 2020;583(7814):139-144
    Baronti L; Guzzetti I; Ebrahimi P; Friebe Sandoz S; Steiner E; Schlagnitweit J; Fromm B; Silva L; Fontana C; Chen AA; Petzold K
  • Article: MOLECULES. 2020;25(5):E1142-1142
    Feyrer H; Munteanu R; Baronti L; Petzold K
  • Journal article: CHEMBIOCHEM. 2019;20(21):2683
    Maru拧i膷 M; Schlagnitweit J; Petzold K
  • Article: CHEMBIOCHEM. 2019;20(19):2474-2478
    Schlagnitweit J; Sandoz SF; Jaworski A; Guzzetti I; Aussenac F; Carbajo RJ; Chiarparin E; Pell AJ; Petzold K
  • Article: METHODS. 2019;162:96-107
    Ebrahimi P; Kaur S; Baronti L; Petzold K; Chen AA
  • Article: CHEMISTRY-A EUROPEAN JOURNAL. 2018;24(23):6067-6070
    Schlagnitweit J; Steiner E; Karlsson H; Petzold K
  • Article: JOURNAL OF BIOMOLECULAR NMR. 2017;69(2):93-99
    Niklasson M; Otten R; Ahlner A; Andresen C; Schlagnitweit J; Petzold K; Lundstrom P
  • Article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2016;55(51):15869-15872
    Steiner E; Schlagnitweit J; Lundstrom P; Petzold K
  • Journal article: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2016;128(51):16101-16104
    Steiner E; Schlagnitweit J; Lundstr枚m P; Petzold K
  • Article: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2015;137(40):12954-12965
    Salmon L; Giambasu GM; Nikolova EN; Petzold K; Bhattacharya A; Case DA; Al-Hashimi HM
  • Article: NATURE. 2015;519(7543):315-320
    Kimsey IJ; Petzold K; Sathyamoorthy B; Stein ZW; Al-Hashimi HM
  • Journal article: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2014;29(12):2353
    Petzold K; Gansevoort RT; Ong ACM; Devuyst O; Rotar L; Eckardt K-U; Koettgen A; Pirson Y; Remuzzi G; Sandford R; Tesar V; Ecder T; Chaveau D; Torra R; Budde K; Le Meur Y; Wuethrich RP; Serra AL
  • Journal article: RESPIROLOGY. 2014;19(1):67-73
    Kuhn H; Petzold K; Hammerschmidt S; Wirtz H
  • Article: JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY. 2013;28(1):78-88
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; Lameira J; Maguire GEM; Soliman MES
  • Article: RSC ADVANCES. 2013;3(45):23355-23360
    Pawar SA; Jabgunde AM; Petzold K; Maguire GEM; Dhavale DD; Kruger HG; Govender T
  • Article: NATURE. 2012;491(7426):724-728
    Dethoff EA; Petzold K; Chugh J; Casiano-Negroni A; Al-Hashimi HM
  • Article: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2012;57:459-467
    Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GEM; Parboosing R; Sayed Y; Soliman MES; Kruger HG
  • Journal article: CHEMMEDCHEM. 2012;7(6):938
    Honarparvar B; Makatini MM; Pawar SA; Petzold K; Soliman MES; Arvidsson PI; Sayed Y; Govender T; Maguire GEM; Kruger HG
  • Article: CHEMMEDCHEM. 2012;7(6):1009-1019
    Honarparvar B; Makatini MM; Pawar SA; Petzold K; Soliman MES; Arvidsson PI; Sayed Y; Govender T; Maguire GEM; Kruger HG
  • Article: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2011;46(9):3976-3985
    Makatini MM; Petzold K; Sriharsha SN; Ndlovu N; Soliman MES; Honarparvar B; Parboosing R; Naidoo A; Arvidsson PI; Sayed Y; Govender P; Maguire GEM; Kruger HG; Govender T
  • Article: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2011;21(8):2274-2277
    Makatini MM; Petzold K; Sriharsha SN; Soliman MES; Honarparvar B; Arvidsson PI; Sayed Y; Govender P; Maguire GEM; Kruger HG; Govender T
  • Article: STRUCTURAL CHEMISTRY. 2011;22(1):161-166
    Shaikh M; Petzold K; Kruger HG; du Toit K
  • Article: TETRAHEDRON ASYMMETRY. 2010;21(23):2859-2867
    Naicker T; Petzold K; Singh T; Arvidsson PI; Kruger HG; Maguire GEM; Govender T
  • Article: MOLECULAR MICROBIOLOGY. 2010;77(6):1539-1555
    Olofsson A; Vallstrom A; Petzold K; Tegtmeyer N; Schleucher J; Carlsson S; Haas R; Backert S; Wai SN; Grobner G; Arnqvist A
  • Article: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 2009;131(40):14150-14151
    Petzold K; Olofsson A; Arnqvist A; Grobner G; Schleucher J
  • Article: CHEMISTRY-A EUROPEAN JOURNAL. 2009;15(3):585-588
    Thiele CM; Petzold K; Schleucher J
  • Article: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. 2008;474(1):39-47
    Petzold K; Ohman A; Backman L
  • Article: NUCLEIC ACIDS RESEARCH. 2007;35(20):6854-6861
    Petzold K; Duchardt E; Flodell S; Larsson G; Kidd-Ljunggren K; Wijmenga S; Schleucher J
  • Article: CELLULAR & MOLECULAR BIOLOGY LETTERS. 2005;10(4):595-612
    Robertsson J; Petzold K; L枚fvenberg L; Backman L
  • Show more

All other publications

  • Conference publication: PROTEIN SCIENCE. 2023;32(12)
    Sahin C; Motso A; Gu X; Feyrer H; Lama D; Arndt T; Rising A; Gese GV; Hallberg M; Marklund EG; Schafer NP; Petzold K; Teilum K
  • Conference publication: BIOPHYSICAL JOURNAL. 2023;122(3):27A
    Petzold K
  • Preprint: BIORXIV. 2022
    Sahin C; Motso A; Gu X; Feyrer H; Lama D; Arndt T; Rising A; Gese GV; H盲llberg M; Marklund E; Schafer N; Petzold K; Teilum K; Wolynes P; Landreh M
  • Preprint: BIORXIV. 2022
    Gr盲tz L; Sajkowska-Kozielewicz J; Wesslowski J; Petzold K; Davidson G; Schulte G; Kozielewicz P
  • Preprint: BIORXIV. 2022
    Feyrer H; Gurdap CO; Maru拧i膷 M; Schlagnitweit J; Petzold K
  • Corrigendum: NUCLEIC ACIDS RESEARCH. 2021;49(12):7204-7205
    Wacker A; Weigand JE; Akabayov SR; Altincekic N; Bains JK; Banijamali E; Binas O; Castillo-Martinez J; Cetiner E; Ceylan B; Chiu L-Y; Davila-Calderon J; Dhamotharan K; Duchardt-Ferner E; Ferner J; Frydman L; Fuertig B; Gallego J; Gruen JT; Hacker C; Haddad C; Haehnke M; Hengesbach M; Hiller F; Hohmann KF; Hymon D; de Jesus V; Jonker H; Keller H; Knezic B; Landgraf T; Loehr F; Luo L; Mertinkus KR; Muhs C; Novakovic M; Oxenfarth A; Palomino-Schaetzlein M; Petzold K; Peter SA; Pyper DJ; Qureshi NS; Riad M; Richter C; Saxena K; Schamber T; Scherf T; Schlagnitweit J; Schlundt A; Schnieders R; Schwalbe H; Simba-Lahuasi A; Sreeramulu S; Stirnal E; Sudakov A; Tants J-N; Tolbert BS; Voegele J; Weiss L; Wirmer-Bartoschek J; Martin MAW; Woehnert J; Zetzsche H
  • Conference publication: BIOPHYSICAL JOURNAL. 2021;120(3):286A
    Petzold K
  • Review: CHEMBIOCHEM. 2019;20(21):2685-2710
    Marusic M; Schlagnitweit J; Petzold K
  • Preprint: BIORXIV. 2019
    Schlagnitweit J; Sandoz SF; Jaworski A; Guzzetti I; Aussenac F; Carbajo RJ; Chiarparin E; Pell AJ; Petzold K
  • Review: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2018;410(14):3239-3252
    Baronti L; Karlsson H; Marusic M; Petzold K
  • Conference publication: FASEB JOURNAL. 2015;29
    Chen Y; Frank A; Petzold K; Liu X; Brooks CIII; Al-Hashimi H; Fierke C
  • Conference publication: ACTA PHYSIOLOGICA. 2014;210:74
    Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Biber J; Jaeger P; Serra AL; Wagner CA
  • Conference publication: FASEB JOURNAL. 2013;27:96.1
    Al-Hashimi H; Petzold K; Chugh J; Mustoe T; Dethoff E; Brooks CIII
  • Other: NATURE CHEMISTRY. 2011;3(12):913-915
    Petzold K; Al-Hashimi HM
  • Conference publication: BIOPHYSICAL JOURNAL. 2009;96(3):409A
    Petzold K; Olofsson A; Arnqvist A; Boren T; Grobner G; Schleucher J
  • Conference publication: ZOONOSES AND PUBLIC HEALTH. 2007;54:93-94
    Olofsson A; Baeckstroem A; Petzold K; Groebner G; Wai SN; Carlsson S; Schleucher J; Arnqvist A
  • Conference publication: BIOPHYSICAL JOURNAL. 2007;:435A
    Petzold K; Bugaytsova J; Olofsson A; Arnqvist A; Aisenbrey C; Boren T; Schleucher J; Grobner G

Grants

  • Swedish Research Council
    1 January 2019 - 31 December 2024
  • Cancer gate holder miR-34a: Understand the structure of the cell's environment
    Swedish Cancer Society
    1 January 2018
    The human genome encodes> 1700 microRNA (miRNA), which controls at least 30% of all proteins expressed. Unregulated miRNA has been found in> 50% of all forms of cancer and thus plays a central role in the development of cancer. Understanding miRNA function and structure is crucial for understanding cancer regulation. The microRNA miR34a, studied in this project, regulates many cancer-related proteins, e.g. Sirt1, CD44, BCL2. A major problem in the current structure determining methods is that it is used in simplified environment, water with small salt. We want to study microRNA structure and regulation in living cells. We use nuclear magnetic resonance (NMR) to illuminate miRNA-mRNA interaction in in vitro environment and in living cells. In addition, we will use biophysical methods to study RNA, e.g. EMSA, UV fusion, fluorescence-based interaction studies, to investigate the structure of miR-34a with different target RNAs in vitro and in living cells. This will lead to a hypothesis of which structure is active with a focus on a specific mRNA under certain environment. We will examine this conformation with modifications on miR-34a and test this structure, in collaboration, about their function in cells and in mice. Since structural change in RNA can control cancer development, this is likely to reveal a whole new level of adjustment of miRNA activities. My research will help to understand the selection process of miRNAs as cancer regulators and therefore will generate important information necessary for innovative development of miRNA tools for cancer and pharmaceutical research. Insights The dynamics of base pairing facilitate predicting other miRNA mRNA complexes and their motions. There is already a miR 34a analog, which is tested in clinical phase 1. Unfortunately, it is unknown how miR 34a is selected for its target mRNA and can therefore create many side effects.
  • MicroRNA adjusts cancer: change the structure to select function
    Swedish Cancer Society
    1 January 2017
    The human genome encodes> 1700 microRNA (miRNA), which controls at least 30% of all proteins expressed. Unregulated miRNA has been found in> 50% of all forms of cancer and thus plays a central role in the development of cancer. Understanding miRNA function and structure is crucial for understanding cancer regulation. The microRNA miR 34a, studied in this project, inactivates the cancer suppressor protein p53 via deacetylation of SIRT1. The mechanism of miR 34a inhibition is not entirely clear due to lack of structural and dynamic information, but to study movement and explain their functions requires observation as in a "movie". We use nuclear magnetic resonance (NMR) to illuminate miRNA-mRNA interaction. This is based on base pair energetics and alternative structure formation and allows fine tuning of miRNA based regulation of translation of cancer-related proteins, such as miR 34a. MiR-34a regulates p53, which has a key role in slowing down cancer. We analyze miRNA mRNA complexes that regulate P53's activity through structural changes. Furthermore, miR 34a has> 50 target mRNA, but it is not understood which mRNA is regulated at any time. We study with NMR, biochemical and in vivo methods how miR 34a selects its correct target from a pool of mRNA (eg, CD44, Jagged, Notch) As structural change in RNA can control cancer development, this is likely to reveal a whole new level of miRNA activity adjustment. My research will help to understand the selection process of miRNAs as cancer regulators and therefore will generate important information necessary for innovative development of miRNA tools for cancer and pharmaceutical research. Insights The dynamics of base pairing facilitate predicting other miRNA-mRNA complexes and their motions. There is already a miR-34a analog, which is tested in clinical phase 1. Unfortunately, it is unknown how miR-34a is selected for its target mRNA and can therefore create many side effects.
  • Knut and Alice Wallenberg Foundation
    1 January 2016 - 1 January 2021
  • MicroRNA adjusts cancer: change the structure to select function
    Swedish Cancer Society
    1 January 2016
    The human genome encodes> 1700 microRNA (miRNA), which controls at least 30% of all proteins expressed. Unregulated miRNA has been found in> 50% of all forms of cancer and thus plays a central role in the development of cancer. Understanding miRNA function and structure is crucial for understanding cancer regulation. The microRNA miR 34a, studied in this project, inactivates the cancer suppressor protein p53 via deacetylation of SIRT1. The mechanism of miR 34a inhibition is not entirely clear due to lack of structural and dynamic information, but to study movement and explain their functions requires observation as in a "movie". We use nuclear magnetic resonance (NMR) to illuminate miRNA-mRNA interaction. This is based on base pair energetics and alternative structure formation and allows fine tuning of miRNA based regulation of translation of cancer-related proteins, such as miR 34a. MiR-34a regulates p53, which has a key role in slowing down cancer. We analyze miRNA mRNA complexes that regulate P53's activity through structural changes. Furthermore, miR 34a has> 50 target mRNA, but it is not understood which mRNA is regulated at any time. We study with NMR, biochemical and in vivo methods how miR 34a selects its correct target from a pool of mRNA (eg, CD44, Jagged, Notch) As structural change in RNA can control cancer development, this is likely to reveal a whole new level of miRNA activity adjustment. My research will help to understand the selection process of miRNAs as cancer regulators and therefore will generate important information necessary for innovative development of miRNA tools for cancer and pharmaceutical research. Insights The dynamics of base pairing facilitate predicting other miRNA-mRNA complexes and their motions. There is already a miR-34a analog, which is tested in clinical phase 1. Unfortunately, it is unknown how miR-34a is selected for its target mRNA and can therefore create many side effects.
  • Swedish Research Council
    1 November 2015 - 30 November 2015
  • RNA switches 鈥 how structural changes influence the function
    Swedish Foundation for Strategic Research
    1 September 2015 - 31 August 2018
  • MicroRNA adjusts cancer: change the structure to select function
    Swedish Cancer Society
    1 January 2015
    The human genome encodes> 1700 microRNA (miRNA), which controls at least 30% of all proteins expressed. Unregulated miRNA has been found in> 50% of all forms of cancer and thus plays a central role in the development of cancer. Understanding miRNA function and structure is crucial for understanding cancer regulation. The microRNA miR 34a, studied in this project, inactivates the cancer suppressor protein p53 via deacetylation of SIRT1. The mechanism of miR 34a inhibition is not entirely clear due to lack of structural and dynamic information, but to study movement and explain their functions requires observation as in a "movie". We use nuclear magnetic resonance (NMR) to illuminate miRNA-mRNA interaction. This is based on base pair energetics and alternative structure formation and allows fine tuning of miRNA based regulation of translation of cancer-related proteins, such as miR 34a. MiR-34a regulates p53, which has a key role in slowing down cancer. We analyze miRNA mRNA complexes that regulate P53's activity through structural changes. Furthermore, miR 34a has> 50 target mRNA, but it is not understood which mRNA is regulated at any time. We study with NMR, biochemical and in vivo methods how miR 34a selects its correct target from a pool of mRNA (eg, CD44, Jagged, Notch) As structural change in RNA can control cancer development, this is likely to reveal a whole new level of miRNA activity adjustment. My research will help to understand the selection process of miRNAs as cancer regulators and therefore will generate important information necessary for innovative development of miRNA tools for cancer and pharmaceutical research. Insights The dynamics of base pairing facilitate predicting other miRNA-mRNA complexes and their motions. There is already a miR-34a analog, which is tested in clinical phase 1. Unfortunately, it is unknown how miR-34a is selected for its target mRNA and can therefore create many side effects.
  • How RNAs move - dynamics of regulatory RNAs
    Ragnar S枚derberg Foundation
    1 January 2015 - 31 December 2019
  • Swedish Research Council
    1 January 2015 - 31 December 2018
  • How do microRNAs select their targets
    Novo Nordisk Foundation
    1 July 2014 - 30 June 2015
  • Swedish Research Council
    1 August 2013 - 31 July 2014

Employments

  • Principal Researcher, Department of Medical Biochemistry and Biophysics, 探花精选, 2022-

Degrees and Education

  • Docent, 探花精选, 2019

News from KI

Events from KI